Advertisement
Advertisement

TRVI

TRVI logo

Trevi Therapeutics Inc

4.51
USD
+0.01
+0.22%
Dec 18, 12:47 UTC -5
Open

Trevi Therapeutics Inc Profile

About

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut.

Info & Links

CEO

Jennifer Good

Headquarters

195 CHURCH STREET, 16TH FLOOR
NEW HAVEN, CT 06510, UNITED STATES

Industry

Biotechnology

Sector

Health Technology

Website

www.trevitherapeutics.com

Auditor

Ernst & Young LLP

Share holders

20

Employees

25

Trevi Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

346.68M

Enterprise Value

330.69M

Enterprise Value/EBITDA(ttm)

-6.88

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

5.13

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-63.31%

Return on Invested Capital(ttm)

-65.66%

Return on Assets(ttm)

-57.06%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-48.07M

Net Income Available to Common(ttm)

-44.32M

Diluted EPS(ttm)

-0.44

Share Statistics

Beta (5Y Monthly)

0.96

52-Week Change

306.31%

S&P 500 52-Week Change

27.90%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

76.87M

Dividend Yield

0.00%

Float4

58.13M

% Held by Insiders

24.37%

% Held by Institutions

95.76%

Balance Sheet

Total Cash(mrq)

65.49M

Total Cash Per Share(mrq)

0.85

Total Debt(mrq)

62.00K

Total Debt/Equity(mrq)

0.11%

Current Ratio(mrq)

7.38%

Quick Ratio(mrq)

7.38%

Book Value Per Share(mrq)

0.78

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.28

Free Cash Flow(ytd)

-28.73M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement